The small-cap Russell 2000 led U.S. stocks lower on Friday — yet it has outperformed all major indexes except the Nasdaq in ...

Silver was sliding Friday, with a drop of 10% in early afternoon trading. That steep drop had the metal heading for its largest one-day decline since Jan. 30, when it plunged 31%, according to Dow ...

Fears of a 2022-style inflation problem are bubbling back up, but there’s also hope for a Trump pivot on the Iran conflict.

A low starting salary, global pandemic, unaffordable housing market, graduate school and two kids didn’t stop Blake Edwards ...

CNBC reported Thursday about the expected timeline for the aerospace company’s prospectus, which would set SpaceX up for a public listing in June. SpaceX did not immediately return MarketWatch’s ...

Former dot-com darlings Intel, Cisco, Qualcomm and Texas Instruments are all hitting record highs — some for the first time ...

As gas prices heat up, there are growing signs that consumers are cooling on big-ticket purchases such as refrigerators, ...

The chip maker’s shares opened 89% above the IPO price before trading was briefly halted for volatility, but then pared some ...

There’s no reason to expect the stock market to struggle this summer. If you think the U.S. stock market’s recent rally ...

The impact of AI capex, the geopolitical race for resources, rising defense spend and a housing shortage in America all argue ...

Dragged down by negative returns for shares of NVIDIA Corp. and Caterpillar, the Dow Jones Industrial Average is in selloff mode Friday morning.

A drug developed by AstraZeneca and Daiichi Sankyo to treat breast cancer has been approved by the Food and Drug Administration. Enhertu was approved for two new breast cancer indications for use ...